<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/060C89E9-66C5-4F7B-B010-218C2A4B88D5"><gtr:id>060C89E9-66C5-4F7B-B010-218C2A4B88D5</gtr:id><gtr:name>Okairos</gtr:name><gtr:address><gtr:line1>Viale Citt? d'Europa, 679</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Experimental Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/060C89E9-66C5-4F7B-B010-218C2A4B88D5"><gtr:id>060C89E9-66C5-4F7B-B010-218C2A4B88D5</gtr:id><gtr:name>Okairos</gtr:name><gtr:address><gtr:line1>Viale Citt? d'Europa, 679</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E89C5F6C-3EB1-417F-943E-127C327DAEDD"><gtr:id>E89C5F6C-3EB1-417F-943E-127C327DAEDD</gtr:id><gtr:firstName>Eleanor</gtr:firstName><gtr:surname>Barnes</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK010239%2F1"><gtr:id>43CD9638-1B04-4B27-9A60-C3E33E988A14</gtr:id><gtr:title>Immunity in the face of diversity and the development of novel potent HCV vaccines</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/K010239/1</gtr:grantReference><gtr:abstractText>The aim of this research is to develop new vaccines against hepatitis C virus (HCV) infection. Importantly, our new vaccines will be effective against different strains of the virus. This is urgently needed as the global burden of HCV infection is immense with 180 million people infected world wide. Within the United Kingdom (UK) 300,000 people are infected. This may lead to liver scarring that progresses to cirrhosis, liver failure and liver cancer. HCV is now the most common reason for liver transplantation in the UK. There is currently no vaccine for either the prevention or the treatment of HCV, and the best available drug treatments are expensive, fraught with side effects, prolonged and frequently ineffective. New drug therapies are on the horizon, but these are only effective against some strains, may be associated with viral resistance, and do not protect against re-infection.

Over centuries, HCV has evolved so that there are now 7 different major viral strains (genotypes) located in particular regions of the world. However, even within a single person, HCV exists as a swarm of closely related but different viruses. Within the UK the two major strains are genotype-1 and genotype-3. The equal prevalence of two genotypes within a country is a unique and special feature of the HCV epidemic in the UK. However, some parts of the virus are the same between strains -these are known as conserved regions. These regions may be the &amp;quot;Achilles heel&amp;quot; of the virus, since a vaccine that effectively targets conserved regions may protect against multiple strains.

So far, we have developed a vaccine that we believe will protect against genotype-1 infection. The vaccine works by stimulating the immune system to make very high number of T cells that attack multiple parts of the virus. We know that T cells are important, since our earlier work showed that these cells are crucial in clearing HCV naturally after infection. Our vaccine is also able to stimulate immune responses in people that are already infected -although responses are weaker in this situation. In this way we hope to use the vaccine to both prevent and eradicate established infection. 

Now we plan to improve our T cell vaccine so that it works against different strains -and especially against both genotypes 1 and 3 in the UK. We will design the vaccine so that the T cells generated by the vaccine target regions that are conserved between viral regions. Once we have developed this, we can test and use the new vaccine in the UK where both genotypes-1 and -3 circulate. We also want to understand why some people respond better than others to vaccination. In addition, whilst we know a lot about the immune system and how it clears genotype-1 virus, we know very little about it clears genotype-3 virus. Understanding these things will allow us to develop new strategies to improve vaccines against HCV. The lessons that we learn in designing a T cell vaccine that is effective against multiple viral strains may also prove useful in combating other variable viruses like HIV and HBV. 

The research is being carried out by Dr. Ellie Barnes (Oxford University). She is collaborating closely with Okairos, a biotechnology company based in Italy, and several investigators from around the world. These collaborations draw together experts in the biology of T cells, vaccinology, and viral sequence analysis and uses new technologies to characterise T cells in great detail. We plan to use blood samples that we have collected from people who have been vaccinated with our vaccines to understand why some people respond better than others. We will design new vaccines against the conserved regions of multiple HCV strains using a database of thousands of HCV sequences that has been developed over the last decade. In this way we will develop a T cell vaccine against HCV that can be used throughout the world and prevent one of the major causes of liver disease.</gtr:abstractText><gtr:technicalSummary>The long term goal is to develop effective T cell vaccines to tackle hepatitis C virus (HCV) diversity. HCV exists globally as seven major genotypes, multiple subtypes and swarms of variants within each host. Within the UK genotype-1 and subtype-3a are equally prevalent - a unique feature of the epidemic. 

To date I have, in collaboration, developed a highly immunogenic HCV T cell vaccine in healthy volunteers. This consists of simian and human adenoviral (Ad) vectors derived from rare serotypes, in addition to Modified Vaccinia Ankara (MVA) vectors, used in heterologous prime/boost regimens. Both vectors encode the entire non-structural (NS) genotype-1b HCV proteins (1995 amino-acids) Significant immunogenicity is also induced in HCV infected patients, though the mean magnitude of the response is lower.

My aims are to identify the determinants of the relative immune non-responsiveness in HCV infected patients. This will be achieved through the detailed characterisation of innate RNA signatures and adaptive T cell immunity, at baseline and in response to vaccination, in association with viral sequence analysis. This will give insight into the mechanism of T cell non-responsiveness that is the hallmark of many persistent viral infections. I will assess the immune correlates of viral clearance in HCV subtype-3a infection through the assessment of T and B cell immunity in natural infection. This will aid the rational design of effective UK HCV vaccines. Finally I will design a prophylactic vaccine for &amp;quot;broad&amp;quot; HCV coverage based on conserved peptide fragments. This will be delivered through the generation of a global relative prevalence HCV subtype dataset, and the &amp;quot;virtual&amp;quot; design of novel immunogens through computer algorithms that interrogate the dataset. Vaccines encoding the novel immunogens will be assessed in pre-clinical models. 

Delivering these aims will facilitate the rational development of novel HCV vaccines within the UK and globally.</gtr:technicalSummary><gtr:potentialImpactText>Beneficiaries of the proposed research; 
The ultimate aim is to develop a prophylactic and therapeutic HCV vaccine that is effective against multiple viral genotypes. This is highly relevant to the UK population that are infected with both subtype-3a and genotype-1, but potential beneficiaries include people globally at risk of HCV (health care workers, intravenous drug users, renal dialysis patients, those living in high HCV prevalence countries, people with HIV, and partners and children of people with HCV) and people with HCV. Major objectives are to understand why people with HCV infection have an attenuated response to potent T cell vaccines, and to develop an effective strategy to tackle viral variability. Achieving these objectives, may protect people from other persistent viruses (HIV and HBV), other variable pathogens (e.g. Dengue), and other diseases where T cells are attenuated in the face of prolonged antigen exposure-such as cancer. 

The generation of the first effective T cell vaccine would drive the commercial and academic sectors that manufacture viral vectors (IDT Germany, CBF, Oxford UK), and who are striving to develop T cell vaccines against a range of pathogens (e.g. RDT-malaria; Okairos-HCV, HIV, malaria and RSV). A successful HCV vaccine would also significantly impact upon public health policy decisions both nationally and globally. 
Societal impacts; The work could be enormously beneficial to health and quality of life globally. HCV currently infects 180 million people worldwide and 4 million people are newly infected annually. Within the UK 0.4% of the population are infected, whilst in other countries the prevalence increases to 10-30% (Egypt and parts of Asia). Many of the people susceptible to HCV exist within vulnerable sectors of society and developing countries, where treatment with current therapies is not an option. 

HIV infected people in particular would benefit from an effective HCV vaccine. By the end of 2010, there were 2.3 million HIV+ people in Europe, of whom over half were co-infected with HCV (WHO data 2011). HCV infection in HIV+ people is associated with an increased risk of developing chronic HCV infection and rapidly progressive liver fibrosis, and is the commonest cause of death in HIV+ people on HAART. Furthermore, there are currently epidemic outbreaks of acute HCV infection in multiple major European cities in men who have sex with men highlighting the failure of preventative measures aimed at changing behaviour. 

New protease inhibitors for HCV represent a major breakthrough in the field, increasing viral clearance rates to 70% for genotype-1. However, these will be ineffective in the 50% of the UK population with genotype-3 infection, and will inevitably be associated with the development of drug resistance. New oral agents currently in development should be available in the future to treat other viral genotypes-but the costs will be prohibitive for the majority. As an analogy, we have had effective treatments with HAART for HIV for over a decade, and yet millions of people around the world have no access to these drugs.

Enhancing economic prosperity;
T cell vaccine technologies are highly competitive at an international level within the UK. The development of the first effective T cell vaccine would place the UK at the forefront of the field. This would increase UK economic prosperity through the commercialisation and exploitation of novel vaccines, and would increase innovative research capacity within academic organisations that seek to develop T cells strategies to combat disease. 

Direct economic savings can also be anticipated since the cost of protease inhibitors is &amp;pound;18,000-&amp;pound;32,000/treatment course. Treatment of only 1% of those currently infected within the UK with these therapies will cost the UK &amp;pound;75 million. 

Realistic time-scales for the benefits to be realised are 5-10 years.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1374784</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Jenner Institute</gtr:department><gtr:description>Jenner Institute</gtr:description><gtr:id>758DF7BC-C773-4C9F-B4BC-14509BBE50B3</gtr:id><gtr:impact>Publication and sharing of expertise</gtr:impact><gtr:outcomeId>dFv4eEAuuMM-1</gtr:outcomeId><gtr:partnerContribution>Expertise in vaccine development</gtr:partnerContribution><gtr:piContribution>HCV vaccine development</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Okairos</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Industry partnership-Okairos</gtr:description><gtr:id>E196D515-1CCA-49D4-ADFD-9E229D8CD057</gtr:id><gtr:impact>Publications</gtr:impact><gtr:outcomeId>iM8TX9eKHiZ-1</gtr:outcomeId><gtr:partnerContribution>Provided vectored vaccines, trial management staff and knowledge.</gtr:partnerContribution><gtr:piContribution>Our phase I vaccine studies are investigator led (staff/immunology assays/analysis and trials are all managed by my team)</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>International Liver Congress, EASL 2017 (Barcelona)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9A5463A9-3D1F-4BD5-829D-05155AF68847</gtr:id><gtr:impact>Registry grant presentation&amp;quot; Thursday 14 April 2016 from 12:00 to 13:30.</gtr:impact><gtr:outcomeId>58beb7994f8d82.34452957</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public event (hosted stall)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EC54A351-B39F-44FF-84C2-CBA52CB7A315</gtr:id><gtr:impact>Stall sparked interest/further questions surounding virology and personalised medicine

Increased awareness for STOP-HCV project - new followers on twitter</gtr:impact><gtr:outcomeId>54633fdb617565.90718176</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BSCGT Public Engagement Event - Vaccines &amp; Infectious Disease (hosted stall)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>11DE3645-3634-4C27-97E8-BB373D0BCF28</gtr:id><gtr:impact>This all-day event included a series of seminars and a 2hr exhibitor event at which STOP-HCV Consortium hosted a stall. ~100-200 delegates registered for the event, and the target audience was primarily secondary school children and the general public. There was a high level of interest in the stall, from both school children and the general public, and the feedback received will inform plans for future events.</gtr:impact><gtr:outcomeId>56dd78e4c7cf00.53263782</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Spotlight on CRN hepatitis C research - interview for website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5E8FA53E-7D86-4056-9AE4-08CD7A79E48D</gtr:id><gtr:impact>Interview for NIHR CRN spotlight on hepatitis C research - published on CRN website</gtr:impact><gtr:outcomeId>56dd954a8d4349.80923505</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.crn.nihr.ac.uk/hepatology/about-hepatology-research/spotlight-on-hepatitis/researcher/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>News letter-viral hepatitis</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>50F395C5-59EC-4945-9800-A6A51D087CB0</gtr:id><gtr:impact>This study was presented in a newsletter on viral hepatitis that is sent to healthcare professionals in Europe.

N/A</gtr:impact><gtr:outcomeId>ArvvkHZvdRq</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public event (hosted stall)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4297AC67-1937-45AC-AF9A-0E7570DE57FF</gtr:id><gtr:impact>Stall sparked questions and answers surrounding virology and personalised medicine

Positive feedback from attendees at the stall resulted in an invitation to host the stall at another public event (Oxford Open Doors)</gtr:impact><gtr:outcomeId>54633e7427d6d5.76164000</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.ndm.ox.ac.uk/cheltenham-science-festival-2014-2</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture series to HCV infected patients</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>223912CE-2187-454D-97CE-813117EDF231</gtr:id><gtr:impact>50 patients and interested health care professionals attended.

Initial talk has turned into a 6 monthly rolling programme.</gtr:impact><gtr:outcomeId>A7ZRgXAH87e</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Oxford Biomedical Research Centre</gtr:department><gtr:description>Oxford NIHR principle fellow award</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Oxford University Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:id>C4C43A5D-E6A1-492A-A57D-75DE4B17EF0C</gtr:id><gtr:outcomeId>56dec530445a84.66068524</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>57000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Global Challenges Research Fund</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A7726D04-2147-46F3-97B5-665E25DED49B</gtr:id><gtr:outcomeId>58c6a815ebc935.25288065</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Generation of a new HCV vaccines</gtr:description><gtr:grantRef>MR/K010239/1</gtr:grantRef><gtr:id>A7752AED-28D9-4B15-AA2D-599A16D6130E</gtr:id><gtr:impact>Not yet</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58c6e4ecb9d437.91019906</gtr:outcomeId><gtr:patentId>1605099.9</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>T cell vaccine for HCV</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>HCV MVA viral vectored vaccine, in phase-I clinical studies, funded by Okairos and the MRC DCS award in collaboration.</gtr:description><gtr:id>3FA088DE-0F07-4A99-A02C-87674BA522F7</gtr:id><gtr:impact>Ni yet</gtr:impact><gtr:outcomeId>r9MypQo9tCr</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>MVA vaccine</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>We have assessed a novel HCV vaccine in healthy volunteers we have shown to be safe and highly immunogenic.</gtr:description><gtr:id>4A44FE16-A671-448E-BB04-BD9C5987CE5C</gtr:id><gtr:impact>Further funding (MRC experimental medicine award) to assess the same vaccine in HCV infected patients has been obtained</gtr:impact><gtr:outcomeId>98434EE1DEC</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>An adenoviral vectored vaccine for HCV infection</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>532C078D-1AA9-44D7-A6EC-2A3F5350FFC3</gtr:id><gtr:title>Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca5128a6373eddbac24c25982b408677"><gtr:id>ca5128a6373eddbac24c25982b408677</gtr:id><gtr:otherNames>van der Ree MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn><gtr:outcomeId>5aa7ccfecec065.98056601</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14ED31E9-89A0-4CDA-8DDE-D7F67A05041A</gtr:id><gtr:title>Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec0ca114a7a974c5bf01b44ab13e9a1e"><gtr:id>ec0ca114a7a974c5bf01b44ab13e9a1e</gtr:id><gtr:otherNames>Banerjee R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>doi_16395_013_09_002</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7BC477B-F483-46BA-A0B5-4EB631392CC6</gtr:id><gtr:title>A modified RNA-Seq approach for whole genome sequencing of RNA viruses from faecal and blood samples.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e96acf7472fed03d888c989d2cbdcf0e"><gtr:id>e96acf7472fed03d888c989d2cbdcf0e</gtr:id><gtr:otherNames>Batty EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16395_25_23762474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55BB4440-CCF9-4A3D-BBD0-11C41DB43BB7</gtr:id><gtr:title>CD8aa Expression Marks Terminally Differentiated Human CD8+ T Cells Expanded in Chronic Viral Infection.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01e010a90f68a03e6f502ca741eaf42f"><gtr:id>01e010a90f68a03e6f502ca741eaf42f</gtr:id><gtr:otherNames>Walker LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>pm_16395_25_23964274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EADB7A4F-8B6C-41C7-9E5E-54DDE27FD921</gtr:id><gtr:title>IGG4-Related Disease is Associatied with CD4+ T Cell Activation and Regulation</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8903b6bcec029c72f58a2deee69073f"><gtr:id>d8903b6bcec029c72f58a2deee69073f</gtr:id><gtr:otherNames>Cargill T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58be87ab185469.31217976</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1550E4B3-1D48-45FD-B855-03EC6AE7A951</gtr:id><gtr:title>Therapeutic vaccines in HBV: lessons from HCV.</gtr:title><gtr:parentPublicationTitle>Medical microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fa373de3f0e9fb2a670e455fccae66e"><gtr:id>3fa373de3f0e9fb2a670e455fccae66e</gtr:id><gtr:otherNames>Barnes E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-8584</gtr:issn><gtr:outcomeId>56cf0142039203.68487792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EFC9109-DB56-477D-9781-7E2831318C22</gtr:id><gtr:title>Enhancement of the Replication of Hepatitis C Virus Replicons of Genotypes 1 to 4 by Manipulation of CpG and UpA Dinucleotide Frequencies and Use of Cell Lines Expressing SECL14L2 for Antiviral Resistance Testing.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdde3fb842addf09615e00c788ae8cd5"><gtr:id>bdde3fb842addf09615e00c788ae8cd5</gtr:id><gtr:otherNames>Witteveldt J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>5759491c181409.33595909</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18FB4D8B-D568-4044-99D6-7E8212A6DC90</gtr:id><gtr:title>Hepatic iron is the major determinant of serum ferritin in NAFLD patients.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5048a6bda99f73fef470ed75036df6ef"><gtr:id>5048a6bda99f73fef470ed75036df6ef</gtr:id><gtr:otherNames>Ryan JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>5aa7ccfea54184.98528958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29A4A38A-49AC-40F8-B6F4-9D6C0665A19E</gtr:id><gtr:title>The emerging mysteries of IgG4-related disease.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50779c75d9ffef688d8c96642422f68c"><gtr:id>50779c75d9ffef688d8c96642422f68c</gtr:id><gtr:otherNames>Smit W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>56cf0142683ed7.11661611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D38ED0DB-FDA0-4DAE-BB8A-52F3A95AE9D6</gtr:id><gtr:title>Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e2623634369ddffd5f2c081a495aba8"><gtr:id>1e2623634369ddffd5f2c081a495aba8</gtr:id><gtr:otherNames>Pedergnana V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56dd92f1060701.66009672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4AB300E5-83CF-42E9-9291-C524035308EA</gtr:id><gtr:title>Thoracic involvement in IgG4-related disease in a UK-based patient cohort.</gtr:title><gtr:parentPublicationTitle>Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddf599c71320cbc39660b2c1596405e6"><gtr:id>ddf599c71320cbc39660b2c1596405e6</gtr:id><gtr:otherNames>Corcoran JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0954-6111</gtr:issn><gtr:outcomeId>5aa7ccfe67c3a3.17220119</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFACD448-8D9D-45D4-9761-3F2C26B6392D</gtr:id><gtr:title>Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f184e1a5169e970ee2668a72321eb0c"><gtr:id>2f184e1a5169e970ee2668a72321eb0c</gtr:id><gtr:otherNames>Thomson E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>58bd4188015e73.32343766</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2E3F519-E4BC-4C57-99C7-A55B33E57865</gtr:id><gtr:title>Apparent spontaneous clearance of chronic hepatitis C virus infection in a HIV co-infected patient with decompensated cirrhosis: a case report.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe12458af70f67e6890a66d553f3c8ee"><gtr:id>fe12458af70f67e6890a66d553f3c8ee</gtr:id><gtr:otherNames>Mora-Peris B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56cf0447126634.42668040</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>883B905F-0390-4725-997A-6A8442066927</gtr:id><gtr:title>Reply to: &amp;quot;Multiparametric magnetic resonance imaging to predict clinical outcomes in patients with chronic liver disease: A cautionary note on a promising technique&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c9b79b1fe97c52865b1ba4070de32f8"><gtr:id>2c9b79b1fe97c52865b1ba4070de32f8</gtr:id><gtr:otherNames>Pavlides M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>58be8d87415d69.11044586</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>505EBD5A-AB06-402D-9EA1-59E7A063A5FE</gtr:id><gtr:title>Phenotypic differences between IgG4+ and IgG1+ B cells point to distinct regulation of the IgG4 response.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/864d12c44cfe8e32ba580fcf7274b599"><gtr:id>864d12c44cfe8e32ba580fcf7274b599</gtr:id><gtr:otherNames>Lighaam LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>doi_16395_013_07_044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA92AE00-9E2E-4AA6-9B77-B1B47F2F2930</gtr:id><gtr:title>Unravelling the fate of functional PD1+ T cells in chronic viral hepatitis.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fa373de3f0e9fb2a670e455fccae66e"><gtr:id>3fa373de3f0e9fb2a670e455fccae66e</gtr:id><gtr:otherNames>Barnes E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>5aa7cc773eeff8.17237270</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04BDA12A-0BCA-40E6-9212-A0F947779A5C</gtr:id><gtr:title>The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5abd39f94d066bac138ba27a82144bac"><gtr:id>5abd39f94d066bac138ba27a82144bac</gtr:id><gtr:otherNames>von Delft A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>58c7dfb19ec7a6.48053862</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C394F4EA-E25A-4E50-B819-E0CA95199383</gtr:id><gtr:title>The Generation of an Immunogenic Second-Generation Conserved Segment HCV T Cell Vaccine to Target Multiple HCV Genotypes</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86d111c0697373d1f23df25dfe5be79b"><gtr:id>86d111c0697373d1f23df25dfe5be79b</gtr:id><gtr:otherNames>Von Delft A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58bd743697d991.05381671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E21FACB1-0CFF-4B34-B9E7-92F76C87813C</gtr:id><gtr:title>Characterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation Sequencing.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e0758eeac82d30f843648ee461fcdb2"><gtr:id>4e0758eeac82d30f843648ee461fcdb2</gtr:id><gtr:otherNames>Iles JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>56cf0446ccc364.63601831</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F501F55-6B31-4066-897A-B3E2800B9B87</gtr:id><gtr:title>Immunology taught by rats.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d9125178bea693a9bb3eae81b908265"><gtr:id>7d9125178bea693a9bb3eae81b908265</gtr:id><gtr:otherNames>Klenerman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>5aa7cd0054afb4.22615846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>857FBE96-A68C-4BB2-931E-20D1DF12DAB6</gtr:id><gtr:title>Immunoglobulin E, Eosinophils and Mast Cells in Atopic Individuals Provide Novel Insights in IGG4-Related Disease</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6d8bf3e8b02adbca2ed2417398e1aec"><gtr:id>b6d8bf3e8b02adbca2ed2417398e1aec</gtr:id><gtr:otherNames>Culver E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58be8c42096a31.55074363</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10E99D74-8C83-4924-A8DE-6E0AC73F3BF4</gtr:id><gtr:title>Ever closer to a prophylactic vaccine for HCV.</gtr:title><gtr:parentPublicationTitle>Expert opinion on biological therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a41629dd60ef372a87a61023cad6c9ac"><gtr:id>a41629dd60ef372a87a61023cad6c9ac</gtr:id><gtr:otherNames>Swadling L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2598</gtr:issn><gtr:outcomeId>pm_16395_25_23651228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C61A924-ADF6-47B5-BEDE-DB99DBB4C956</gtr:id><gtr:title>Sequencing Methods Developed for Hepatitis C Identifies a New Virus, Human Hepegivirus 1, in Patients with Advanced Cirrhosis</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e5447a20e5237a088883e190d3b9dae"><gtr:id>5e5447a20e5237a088883e190d3b9dae</gtr:id><gtr:otherNames>Bonsall D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58bd73e8b7dfe2.35026672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34E8DD52-BB49-4C5B-B7FB-8B152FDF711C</gtr:id><gtr:title>No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort.</gtr:title><gtr:parentPublicationTitle>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a50b7f86a652517d0cb7d1da4d96b549"><gtr:id>a50b7f86a652517d0cb7d1da4d96b549</gtr:id><gtr:otherNames>Culver EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1424-3903</gtr:issn><gtr:outcomeId>5aa7cd007a6988.71727651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B3E9CC2-ECDC-4722-B468-3FC1F8CFC095</gtr:id><gtr:title>Hepitopes: A live interactive database of HLA class I epitopes in hepatitis B virus.</gtr:title><gtr:parentPublicationTitle>Wellcome open research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da32190c31487b37501af20bf20e9bba"><gtr:id>da32190c31487b37501af20bf20e9bba</gtr:id><gtr:otherNames>Lumley S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2398-502X</gtr:issn><gtr:outcomeId>58bd429aa02510.74617763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>452DCA54-F72F-4D9C-86F8-9EE4119A39F4</gtr:id><gtr:title>Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa56070c948c0fb966fe86c46b8bd5f7"><gtr:id>aa56070c948c0fb966fe86c46b8bd5f7</gtr:id><gtr:otherNames>Foster GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>58c6c082229e36.55350653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12CCB791-3F57-4279-B25C-FEF06A16FE34</gtr:id><gtr:title>MAIT cells are activated during human viral infections.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd9c5d3ad67e5b8adc8f4409ebdea785"><gtr:id>fd9c5d3ad67e5b8adc8f4409ebdea785</gtr:id><gtr:otherNames>van Wilgenburg B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58bd40e9b97e37.66281318</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>234C75BF-8236-4D45-813C-E20D162789EE</gtr:id><gtr:title>Prevention of infection caused by immunosuppressive drugs in gastroenterology.</gtr:title><gtr:parentPublicationTitle>Therapeutic advances in chronic disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4719d6cb46ccfc1a84dfd95e3c0617d2"><gtr:id>4719d6cb46ccfc1a84dfd95e3c0617d2</gtr:id><gtr:otherNames>Orlicka K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2040-6223</gtr:issn><gtr:outcomeId>pm_16395_25_23819020</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC9D448D-5289-440A-BACD-2020041D8283</gtr:id><gtr:title>Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G 4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37b94a02c3da54792b6928ea4c6f4c23"><gtr:id>37b94a02c3da54792b6928ea4c6f4c23</gtr:id><gtr:otherNames>Doorenspleet ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>58bd41e2e83147.01675728</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CBCFEAA-06B9-44F1-B76D-666D5A43773B</gtr:id><gtr:title>Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort.</gtr:title><gtr:parentPublicationTitle>The American journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27e30c1e6d081c1532706adeec54bc38"><gtr:id>27e30c1e6d081c1532706adeec54bc38</gtr:id><gtr:otherNames>Huggett MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0002-9270</gtr:issn><gtr:outcomeId>54637864ccc546.50054681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DF08578-7EC2-48F1-A84F-20B690ECE552</gtr:id><gtr:title>Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c9b79b1fe97c52865b1ba4070de32f8"><gtr:id>2c9b79b1fe97c52865b1ba4070de32f8</gtr:id><gtr:otherNames>Pavlides M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>58c7e092d05db8.32330271</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D41D6247-F48D-48F7-9AF2-CF3C2A3D3387</gtr:id><gtr:title>Increases in IgE, Eosinophils, and Mast Cells Can be Used in Diagnosis and to Predict Relapse of IgG4-Related Disease.</gtr:title><gtr:parentPublicationTitle>Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a50b7f86a652517d0cb7d1da4d96b549"><gtr:id>a50b7f86a652517d0cb7d1da4d96b549</gtr:id><gtr:otherNames>Culver EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1542-3565</gtr:issn><gtr:outcomeId>58bd56549f9911.34186412</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03AD3CBB-A2C1-4D52-B85D-7F7C6D5171CA</gtr:id><gtr:title>Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa56070c948c0fb966fe86c46b8bd5f7"><gtr:id>aa56070c948c0fb966fe86c46b8bd5f7</gtr:id><gtr:otherNames>Foster GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>56d8380ee5a8d5.99914806</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49172280-AADE-4E6F-B18D-9741403C5488</gtr:id><gtr:title>Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d70dc7bb49a750d51b5f50e44caa910f"><gtr:id>d70dc7bb49a750d51b5f50e44caa910f</gtr:id><gtr:otherNames>Kelly C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>54637864f09470.73717229</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CD18BAB-93E5-470C-958C-425AD5D16AFF</gtr:id><gtr:title>Treatment Outcomes and Drug-Related Adverse Effects in IGG4-Related Disease</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23d2c150c98fff2c7d9065b13f62b255"><gtr:id>23d2c150c98fff2c7d9065b13f62b255</gtr:id><gtr:otherNames>Manganis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58be8cb94ef835.59086148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DB0A6C8-FD0C-4FB5-B96D-60AE01FE39C3</gtr:id><gtr:title>Effect of interferon-a on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880cf52474bd701e7fe0e2f26464865f"><gtr:id>880cf52474bd701e7fe0e2f26464865f</gtr:id><gtr:otherNames>Taylor MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>pm_16395_25_23659574</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C1A2E7E-347B-4FA1-8CC2-6A9D2FBF4FEC</gtr:id><gtr:title>Characterization of the Specificity, Functionality, and Durability of Host T-Cell Responses Against the Full-Length Hepatitis E Virus.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ff5c71c07b14727cc3d86a39f46a326"><gtr:id>7ff5c71c07b14727cc3d86a39f46a326</gtr:id><gtr:otherNames>Brown A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>58bd56045838a2.13793750</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A3C54F6-4E94-4FCB-AA28-4DA1486EB3E8</gtr:id><gtr:title>Adenoviral Vector Vaccination Induces a Conserved Program of CD8(+) T Cell Memory Differentiation in Mouse and Man.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5790411e8c5d561eee2f8a97bfbd48e"><gtr:id>c5790411e8c5d561eee2f8a97bfbd48e</gtr:id><gtr:otherNames>Bolinger B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d8380f80d9d3.81624553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9083EAB8-5141-4D8E-8F9A-7EF52143670F</gtr:id><gtr:title>PTH-092&amp;nbsp;Discovery and quantitation of novel liver fibrosis biomarkers using proteomics</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee8e47d5ca2ed34b98bf9e47c41be102"><gtr:id>ee8e47d5ca2ed34b98bf9e47c41be102</gtr:id><gtr:otherNames>Gangadharan B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d83b33441586.13723445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D6F7809-BA9D-4738-A473-2410A49BADE3</gtr:id><gtr:title>Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR.</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e5447a20e5237a088883e190d3b9dae"><gtr:id>5e5447a20e5237a088883e190d3b9dae</gtr:id><gtr:otherNames>Bonsall D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn><gtr:outcomeId>56d84584cb4de0.62995936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF50586D-A3E6-4D83-9114-F0E7561781E5</gtr:id><gtr:title>Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d582accefa04f804d6bab230d9dd36e"><gtr:id>5d582accefa04f804d6bab230d9dd36e</gtr:id><gtr:otherNames>Martin NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56dd7bdf095a29.42778603</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12DA6749-1822-4BDD-8354-6229721C691E</gtr:id><gtr:title>Multi-Parametric Magnetic Resonance Imaging of the Spleen: An Accurate and Non-Invasive Biomarker of Portal Pressure</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c9b79b1fe97c52865b1ba4070de32f8"><gtr:id>2c9b79b1fe97c52865b1ba4070de32f8</gtr:id><gtr:otherNames>Pavlides M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58bd7481525436.85490745</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9A65972-CFDD-418A-9FAF-E52A60BD32EF</gtr:id><gtr:title>Treatment of chronic viral hepatitis C in children and adolescents: UK experience.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a329b08724325adbf88ee4f407198a31"><gtr:id>a329b08724325adbf88ee4f407198a31</gtr:id><gtr:otherNames>Abdel-Hady M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>doi_16395_013_304601</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5754140A-07F7-4FA0-B4FC-56281D38ECB6</gtr:id><gtr:title>ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens.</gtr:title><gtr:parentPublicationTitle>F1000Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e5447a20e5237a088883e190d3b9dae"><gtr:id>5e5447a20e5237a088883e190d3b9dae</gtr:id><gtr:otherNames>Bonsall D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2046-1402</gtr:issn><gtr:outcomeId>56d847771c2be5.87628688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>460690C2-82E9-45F3-8D46-888CA3DBC21E</gtr:id><gtr:title>British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc7a3915b3381a251f20216e005b759d"><gtr:id>dc7a3915b3381a251f20216e005b759d</gtr:id><gtr:otherNames>Wilkins E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>doi_16395__hiv_12106</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>374855A1-C430-4110-BEFB-C37BC60014B7</gtr:id><gtr:title>Hepatitis B vaccine shortage: another symptom of chronic neglect?</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fb25d83715c29e0eaf7b3a566c436ba"><gtr:id>0fb25d83715c29e0eaf7b3a566c436ba</gtr:id><gtr:otherNames>Matthews PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>5aa7ccfef08a43.43408351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17EB395D-4780-47F8-A565-717E255FB804</gtr:id><gtr:title>Human Leucocyte Antigen Associations in IGG4-Related Disease and Primary Sclerosing Cholangitis Stratified by IGG4 Levels, in a Multicenter UK Cohort</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6d8bf3e8b02adbca2ed2417398e1aec"><gtr:id>b6d8bf3e8b02adbca2ed2417398e1aec</gtr:id><gtr:otherNames>Culver E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58be8bb4376202.59471682</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26B0CE12-FCFA-4794-8E1E-770BDBC64B17</gtr:id><gtr:title>Phosphodiester content measured in human liver by in vivoP MR spectroscopy at 7 tesla.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdf412ed0c1e5ef6b7c1639128d8cc81"><gtr:id>bdf412ed0c1e5ef6b7c1639128d8cc81</gtr:id><gtr:otherNames>Purvis LAB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0740-3194</gtr:issn><gtr:outcomeId>58bd720fc76e42.58937262</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36E37344-A5AE-4A7C-8C26-7A6ADDA98919</gtr:id><gtr:title>The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5abd39f94d066bac138ba27a82144bac"><gtr:id>5abd39f94d066bac138ba27a82144bac</gtr:id><gtr:otherNames>von Delft A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5a6f2d2ba3c8c5.02680253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6826F0A-31B7-4D30-A70E-694C73B08D12</gtr:id><gtr:title>Joint whole-genome analysis of associations between host and hepatitis C virus diversity in a patient cohort.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e2623634369ddffd5f2c081a495aba8"><gtr:id>1e2623634369ddffd5f2c081a495aba8</gtr:id><gtr:otherNames>Pedergnana V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56dd9218740bc4.63881848</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>304988CC-5F99-45FF-BA5E-14740F6707D7</gtr:id><gtr:title>Elevated Serum IgG4 Levels in Diagnosis, Treatment Response, Organ Involvement, and Relapse in a Prospective IgG4-Related Disease UK Cohort.</gtr:title><gtr:parentPublicationTitle>The American journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a50b7f86a652517d0cb7d1da4d96b549"><gtr:id>a50b7f86a652517d0cb7d1da4d96b549</gtr:id><gtr:otherNames>Culver EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9270</gtr:issn><gtr:outcomeId>58bd3c749af651.89919507</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B31D494-7ADF-42BD-845F-098C763DDD91</gtr:id><gtr:title>Interferon-a induces negative biases in emotional processing in patients with hepatitis C virus infection: a preliminary study.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/377ce07d9b305025f968216d5044b1e4"><gtr:id>377ce07d9b305025f968216d5044b1e4</gtr:id><gtr:otherNames>Cooper CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>5aa7ccff2b3ec8.64430605</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E96981E-D0F5-4E0F-8F13-874119813329</gtr:id><gtr:title>Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines.</gtr:title><gtr:parentPublicationTitle>Human vaccines &amp; immunotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03bf3021d170ffb53155b63a4e9d5cf8"><gtr:id>03bf3021d170ffb53155b63a4e9d5cf8</gtr:id><gtr:otherNames>Rowland R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2164-5515</gtr:issn><gtr:outcomeId>doi_16395_1_hv_24998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F552EBF-7A40-4A0B-BDCF-FE9701AFBBEF</gtr:id><gtr:title>Increased IgG4 responses to multiple food and animal antigens indicate a polyclonal expansion and differentiation of pre-existing B cells in IgG4-related disease.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a50b7f86a652517d0cb7d1da4d96b549"><gtr:id>a50b7f86a652517d0cb7d1da4d96b549</gtr:id><gtr:otherNames>Culver EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>56cf006661c671.50746975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D2F704D-76F5-4128-BB44-7CD0871A264A</gtr:id><gtr:title>Screening and treatment for hepatitis C: a balanced perspective.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fb25d83715c29e0eaf7b3a566c436ba"><gtr:id>0fb25d83715c29e0eaf7b3a566c436ba</gtr:id><gtr:otherNames>Matthews PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>56cf0447398c32.73180600</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>696C9322-FB76-4AA5-AA5A-9B2F111E60E3</gtr:id><gtr:title>Liver and Systemic Iron Loading Characterise Initial Disease Progression in Non-Alcoholic Fatty Liver Disease</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b61412769c5cf503a809c3adc79ed53"><gtr:id>5b61412769c5cf503a809c3adc79ed53</gtr:id><gtr:otherNames>Ryan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58bd74ce6b3701.77274384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71B237C0-9807-403B-B62B-33605EFDCA4F</gtr:id><gtr:title>Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.</gtr:title><gtr:parentPublicationTitle>Vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a41629dd60ef372a87a61023cad6c9ac"><gtr:id>a41629dd60ef372a87a61023cad6c9ac</gtr:id><gtr:otherNames>Swadling L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2076-393X</gtr:issn><gtr:outcomeId>58bd55299309f0.03093851</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92FA0EDF-FEB8-4037-832F-B22D96AB94F5</gtr:id><gtr:title>P207 Thoracic involvement in IgG4-related disease</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3980b12d877402ea26bea157de4598a"><gtr:id>c3980b12d877402ea26bea157de4598a</gtr:id><gtr:otherNames>Anstey R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>58c7e1d54faa91.47569020</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A3FDC63-723A-48D3-8DD7-214C5C2C2DD0</gtr:id><gtr:title>Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39e0393fc48fdd4da51e569bcdfa0f75"><gtr:id>39e0393fc48fdd4da51e569bcdfa0f75</gtr:id><gtr:otherNames>Stelma F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5a2fd650999d96.39117818</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96002FF1-C879-42D9-BBD9-A9AFFB8702F4</gtr:id><gtr:title>A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a41629dd60ef372a87a61023cad6c9ac"><gtr:id>a41629dd60ef372a87a61023cad6c9ac</gtr:id><gtr:otherNames>Swadling L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>56cf0142977a56.94989413</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD1A2A6F-C313-483F-A98C-771D451279B4</gtr:id><gtr:title>Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d70dc7bb49a750d51b5f50e44caa910f"><gtr:id>d70dc7bb49a750d51b5f50e44caa910f</gtr:id><gtr:otherNames>Kelly C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56d8380f5335e8.43616576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10801BF0-1E36-4DD1-A11C-9F05EAF421DC</gtr:id><gtr:title>A 63-year-old man with a recurrent right-sided pleural effusion.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddf599c71320cbc39660b2c1596405e6"><gtr:id>ddf599c71320cbc39660b2c1596405e6</gtr:id><gtr:otherNames>Corcoran JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>56cf014237e755.14865025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71DE078B-2556-4A78-B1ED-A7B87DEFA874</gtr:id><gtr:title>Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c9b79b1fe97c52865b1ba4070de32f8"><gtr:id>2c9b79b1fe97c52865b1ba4070de32f8</gtr:id><gtr:otherNames>Pavlides M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>58bd422be49706.83948894</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDF20F24-2758-496F-91E9-F7E5F244FB6C</gtr:id><gtr:title>Infection frequency of hepatitis C virus and IL28B haplotypes in Papua New Guinea, Fiji, and Kiribati.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/930482e97c201621a2f1dceb5bf11fa0"><gtr:id>930482e97c201621a2f1dceb5bf11fa0</gtr:id><gtr:otherNames>Harrison GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16395_25_23976941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E948387D-90A9-408B-B16B-C56970F00A5A</gtr:id><gtr:title>Helicobacter Pylori as a Microbial Antigen in IGG4-Related Disease</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6d8bf3e8b02adbca2ed2417398e1aec"><gtr:id>b6d8bf3e8b02adbca2ed2417398e1aec</gtr:id><gtr:otherNames>Culver E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58be8a3eb495b6.83332417</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4234DCDA-8650-4BFA-B060-E96CF4E73D0C</gtr:id><gtr:title>Emergence of a distinct HIV-specific IL-10-producing CD8+ T-cell subset with immunomodulatory functions during chronic HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd46411c37ebf6a7f879374f9fe427a2"><gtr:id>fd46411c37ebf6a7f879374f9fe427a2</gtr:id><gtr:otherNames>Clutton G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>doi_16395__201343646</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87235C05-7FDF-4D80-BCF4-F250E90FA5AB</gtr:id><gtr:title>An expanded taxonomy of hepatitis C virus genotype 6: Characterization of 22 new full-length viral genomes.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9a3aa67a5e6a2ba5c8d8092e120270b"><gtr:id>d9a3aa67a5e6a2ba5c8d8092e120270b</gtr:id><gtr:otherNames>Li C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>56cf0066b39c29.40772316</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEC67F96-AD5B-4879-AB07-515B83A73A60</gtr:id><gtr:title>Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3666cf06444ddb02f1252399aec841f"><gtr:id>a3666cf06444ddb02f1252399aec841f</gtr:id><gtr:otherNames>Boonstra K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>54637865449289.36855178</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D1B3202-5568-41B4-B006-FB7B46FEFE66</gtr:id><gtr:title>CD161(int)CD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/631403af319e101b8cce9c394f2144fb"><gtr:id>631403af319e101b8cce9c394f2144fb</gtr:id><gtr:otherNames>Fergusson JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>56ceffee13dfa9.26582367</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99F1B3EE-A65B-4952-9082-96D88A2F5585</gtr:id><gtr:title>Hepatitis E virus infection, Papua New Guinea, Fiji, and Kiribati, 2003-2005.</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b3fa835057d57bf020eefe10194f18c"><gtr:id>0b3fa835057d57bf020eefe10194f18c</gtr:id><gtr:otherNames>Halliday JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn><gtr:outcomeId>54637865212406.93735414</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9055B9B4-C61F-438C-A1A5-AF2D833D7CAE</gtr:id><gtr:title>Interobserver Variability in Histologic Evaluation of Liver Fibrosis Using Categorical and Quantitative Scores.</gtr:title><gtr:parentPublicationTitle>American journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c9b79b1fe97c52865b1ba4070de32f8"><gtr:id>2c9b79b1fe97c52865b1ba4070de32f8</gtr:id><gtr:otherNames>Pavlides M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9173</gtr:issn><gtr:outcomeId>5aa7cd00c20f48.50965825</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55C12A97-CCA6-4416-AFBB-1094627DD840</gtr:id><gtr:title>Global distribution and prevalence of hepatitis C virus genotypes.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b908e6ceb5ed4e4f707b25951b2ffc24"><gtr:id>b908e6ceb5ed4e4f707b25951b2ffc24</gtr:id><gtr:otherNames>Messina JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5463262d7d2705.86760248</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K010239/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>